Investor Presentaiton slide image

Investor Presentaiton

IV Appendix Income Statement In EGP Gross Revenue 4Q2018 4Q2019 YOY▲ 3,995,353 4,783,860 19.7% FY2018 13,677,881 FY2019 16,941,029 YOY 23.9% Net Revenue 3,890,288 4,671,104 20.1% 13,323,674 16,600,460 24.6% Cost of Revenue (3,573,779) (4,276,757) Gross Profit Gross Profit Margin 316,509 8.14% 394,346 24.6% 8.44% Selling, General & Administrative (174,646) (200,863) (12,199,359) 1,124,315 8.44% (569,491) (15,161,005) 1,439,455 8.67% (689,229) 28.0% EBITDA 141,863 193,484 36.4% 554,824 750,226 35.2% EBITDA Margin 3.65% 3.90% 4.16% 4.52% Depreciation & Amortization (3,314) (27,795) (41,421) (86,229) EBIT EBIT Margin Financial Expenses Other Expenses 160,483 109,523 -31.8% 513,403 663,996 29.3% 3.56% (39,476) 3.55% 3.85% (89,225) (25,198) 508 (125,843) (59,360) 4.00% (252,510) (15,193) Other Income 25,327 23,112 27,657 24,590 EBT 99,202 100,084 0.9% 355,856 420,883 18.3% EBT Margin 2.55% 2.14% 2.67% 2.54% Deferred Tax (1,672) (5,166) (650) 344 Income Tax (25,600) (12,726) (92,684) (92,456) Net Profit 71,930 82,193 14.3% 262,522 328,771 25.2% Net Profit Margin 1,85% 1.76% 1.97% 1.98% EPS 0.13 0.05 0.36 0.40 ibnsinapharma Source: Company Management (1) Gross revenue includes transportation revenue 32 32
View entire presentation